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Racial differences on the outcome of simultaneous
pancreas and kidney (SPK) transplantation have not
been well studied. We compared mortality and graft
survival of African Americans (AA) recipients to other
racial/ethnic groups (non-AA) using the national data.
We studied a total of 6585 adult SPK transplants per-
formed in the United States between January 1, 2000
and December 31, 2007. We performed multivariate lo-
gistic regression analyses to determine risk factors as-
sociated with early graft failure and immune-mediated
late graft loss. We used conditional Kaplan–Meier sur-
vival and multivariate Cox regression analyses to es-
timate late death-censored kidney and pancreas graft
failure and death between the groups. Although there
was no racial disparity in the first 90 days, AA pa-
tients had 38% and 47% higher risk for late death-
censored kidney and pancreas graft failure, respec-
tively (p = 0.006 and 0.001). AA patients were twice
more likely to lose the kidney and pancreas graft due
to rejection (OR 2.31 and 1.86, p = 0.002 and 0.008, re-
spectively). Bladder pancreas drainage was associated
with inferior patient survival (HR 1.42, 95% CI 1.15, 1.75,
p = 0.001). In the era of modern immunosuppresion,
AA SPK transplant patients continue to have inferior
graft outcome. Additional studies to explore the mech-
anisms of such racial disparity are warranted.
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Introduction
Simultaneous pancreas and kidney (SPK) transplantation
is the preferred treatment modality for suitable type 1 di-
abetic patients with end stage renal disease (ESRD) (1–3).
Beside improvement in quality of life, evidence suggests
that a successful SPK transplant has the potential to im-
prove cardiovascular risk profile, reduce the progression of
macrovascular complication of diabetes and improve pa-
tient survival (4–10). With the introduction of more potent
immunosuppressive medications as maintenance therapy
and widespread use of induction agents, the incidence of
acute rejection has decreased and patient and graft sur-
vival has improved in SPK transplant patients in the recent
era (11,12).
Although the incidence of type 1 diabetes mellitus in
African Americans (AA) is lower than that of non-Hispanic
white population, the AA diabetic patients have poorer
metabolic control and higher incidence of end organ dam-
age including ESRD (13–18). Type 1 diabetic AA ESRD pa-
tients have lower rate of access to SPK transplant registra-
tion compared to Caucasians (19,20). It is unclear whether
such lower access to SPK transplantation in AA is the result
of referral bias due to perceived inferiority in the outcome
of SPK transplant for AA patients (20). AA kidney trans-
plant patients have higher risk for kidney graft loss and
require increased levels of immunosuppression (21–25).
However, literature on such racial disparity regarding pan-
creas transplant outcome in the setting of SPK transplan-
tation remains limited and controversial as most reports
were generated from small numbers of AA SPK transplant
patients involved in clinical trials or in single-center studies
(26–28).
We hypothesized that with the improvement in surgical
technique and perioperative care, as well as enhanced im-
munosuppression, both in term of induction and mainte-
nance regimens, in the recent era, there would be no racial
disparity in the outcome in SPK transplantation between
AA and non-AA patients. We undertook a retrospective
analysis of national registry data to determine race-specific
graft survival and mortality risk among SPK transplant pa-
tients. Because early pancreas graft failure is not a rare
event that may contribute to the difference in overall graft
survival, we separately assessed the race-specific risks of
early and late graft loss.
Methods
We included all adult primary simultaneous pancreas and kidney (SPK) trans-
plants performed between January 1, 2000 and December 31, 2007 in the
United States in the national database provided by the Organ Procurement
and Transplantation Network (OPTN)/Scientific Registry of Transplant Recip-
ients (SRTR). The SRTR data system includes data on all donors, wait-listed
candidates and transplant recipients in the US, submitted by the members
of the OPTN, and has been described elsewhere (29). The Health Resources
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and Services Administration (HRSA), U.S. Department of Health and Human
Services provides oversight to the activities of the OPTN and SRTR contrac-
tors. The study was approved by the Institutional Review Board (IRB). The
follow-up was up to November 30, 2008. We performed separate analyses
for early and late graft failure and death. We defined early graft failure as
kidney and/or pancreas loss within the first 90 days after transplantation
(30,31). The causes of early and late graft failure were separately exam-
ined. Baseline recipient and donor-related characteristics were examined
and used in multivariate analyses as appropriate. Surgical modalities in ex-
ocrine pancreas anastomosis were identified and included as one of the
covariates in the analyses. The use of various immunosuppressive agents,
induction and maintenance, and their various combinations were obtained
from the initial hospital discharge and incorporated in the analyses. Trans-
plant centers were grouped according to the volume of SPK transplants
performed at a given year and used as a covariate in the multivariate analy-
ses.
Demographic and baseline characteristics were compared using Student’s
t-test and v 2-test between AA and non-AA SPK transplant patients. For early
graft failure (within 90 days of transplant), a multivariate logistic regression
model was used to identify the risk factors associated with graft failure
adjusting the volume of SPK transplants at individual centers. For late out-
come, conditional Kaplan–Meier survival and multivariate Cox proportional
regression analysis with backward selection approach was performed for all
SPK patients who had survived up to 90 days after transplantation with both
functioning grafts for composite transplant outcome including graft failure
(kidney and/or pancreas) and death, and subsequently for death-censored
graft survival and patient survival. Finally, the causes of late pancreas and
kidney graft loss were identified and a multivariate logistic regression was
performed to identify the risk factors associated with acute and chronic
rejection related graft loss. Software SAS 9.1 was utilized and statistical
significance was set at p ≤ 0.05.
Results
A total of 6742 adult de novo SPK transplant patients were
identified in the OPTN/SRTR data set between January
1, 2000 and December 31, 2007. After excluding patients
who had incomplete or overlapping information on their
initial immunosuppression regimens and final outcome and
early loss to follow-up (<90 days), the final cohort included
6585 SPK patients. Among these, 931 (14.1%) reported
African American as their racial category. The remainders
(5654) were classified as non-AA SPK transplant patients.
During the study period, the volume of SPK transplants has
remained relatively stable for AA and non-AA patients.
Table 1 shows the demographic and baseline characteris-
tics of study population. Compared to non-AA SPK trans-
plant patients, AA SPK transplant patients were younger
(38.5 ± 8.6 years vs. 41.9 ± 8.3 years, p < 0.001) with
lower body mass index (BMI) (24.6 ± 4.0 vs. 25.0 ± 4.0,
p = 0.01), had shorter duration of diabetes (22.9 ± 7.5
years vs. 27.1 ± 8.1 years, p < 0.001), lower proportion of
patients with type 1 diabetes mellitus (90.4% vs. 94.2%,
p < 0.001) and longer duration of ESRD (2.3 ± 1.9 years
vs. 1.6 ± 1.8 years, p < 0.001). AA SPK transplant pa-
tients also had lower rate of preemptive transplant (2.5%
vs. 10.0%, p < 0.001), more frequent previous blood trans-
fusion (30.2% vs. 24.5%, p < 0.001), higher levels of panel
reactive antibodies at transplant (9.2 ± 20.6 vs. 7.3 ± 18.2,
p = 0.008) and received more often organs from younger
donors (26.0 ± 10.0 years vs. 26.9 ± 10.8 years, p = 0.007)
and AA donors (23.6% vs. 13.4%, p < 0.001). The level of
human leukocyte antigen (HLA) mismatch was 4.7 ± 1.0
in AA versus 4.4 ± 1.3 in non-AA SPK transplant patients,
respectively (p < 0.001). The delayed kidney graft func-
tion was 13.0% in AA compared to 7.2% in non-AA SPK
transplant patients (p < 0.001). Fewer AA SPK transplant
patients had history of coronary artery disease (4.9% vs.
9.1%, p < 0.001) and peripheral vascular disease (4.8%
vs. 7.1%, p = 0.01) prior to transplantation. AA SPK trans-
plant patients also were less likely to have private health
insurance (31.0% vs. 51.7%, p < 0.001).
Induction therapy was used among 78.1% of SPK trans-
plant patients with majority of patients receiving T-cell-
depleting antibodies (46.6%). Alemtuzumab was used in
7.5% and interleukin 2 receptor (IL-2R) blockers in 23.3% of
patients, respectively. Tacrolimus was the most commonly
used calcineurin inhibitor (87.2%) and mycophenolate
mofetil/mycophenolic sodium the predominant antiprolif-
erative agent used (83.4%). In addition, 96.1% of SPK pa-
tients were receiving steroids at the time of discharge.
From the initial transplant hospitalization, the combination
of tacrolimus and mycophenolate mofetil/mycophenolic
sodium accounted for 75% of maintenance regimen at
the time of discharge.
The volume of SPK transplants performed by transplant
centers across the United States varies from as few as 1
to as many as 59 per year during the study period (mean
16 and median 13). The enteric exocrine pancreas drainage
was used in 82.0% of SPK transplants with no difference
between AA and non-AA SPK patients. The use of enteric
drainage surgical technique increased over the study period
from 71.2% in 2000 to 87.0% in 2007 (p < 0.001).
Early pancreas graft failure (less than 90 days posttrans-
plant) is common affecting approximately 10% of SPK
transplant patients (31,32). The leading causes of early fail-
ure were thrombosis, leak and infection. A total of 585 pan-
creas (8.9%) and 149 kidney (2.3%) graft were lost within
initial 90 days. The most common reason for graft loss
was thrombosis, which accounted for 56.1% of pancreas
loss and 35.6% of kidney loss, respectively. Multivariate
logistical analyses showed that recipient race had no ef-
fect on the risk of early kidney or pancreas graft failure (OR
1.09, 95% CI 0.70, 1.69, p = 0.72 for kidney loss, and OR
0.92, 95% CI 0.71, 1.18, p = 0.44 for pancreas loss). Fe-
male recipients (OR 1.62, 95% CI 1.14, 2.31, p = 0.008),
delayed kidney graft function (OR 15.75, 95% CI 10.96,
22.62, p < 0.001), older donor age (OR 1.02, 95% CI 1.00,
1.03, p = 0.05), African American donors (OR 1.66, 95%
CI 1.08, 2.54, p = 0.02), hypertensive donors (OR 1.86,
95%CI 1.09, 3.15, p = 0.02) and bladder pancreas drainage
(OR 1.59, 95% CI, 1.07, 2.37, p = 0.02) were associated
with increased risk of early kidney graft failure. Female
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Table 1: Baseline demographic and clinical characteristics of study population
Non-AA SPK AA SPK
N = 5654 N = 931 p-Value
Age (years) (SD) 41.9 (8.3) 38.5 (8.6) <0.001
Gender, male (%) 3512 (62.1) 553 (59.4) 0.11
Body mass index (kg/m2) (SD) 25.0 (4.0) 24.6 (4.0) 0.01
Duration of diabetes (years) (SD) 27.1 (8.1) 22.9 (7.5) <0.001
Patients with type 1 diabetes mellitus (%) 5323 (94.2) 842 (90.4) <0.001
Years of dialysis (SD) 1.6 (1.8) 2.3 (1.9) <0.001
History of dialysis (%)
Non dialysis 563 (10.0) 23 (2.5) <0.001
<1 year 1935 (34.2) 213 (22.9)
1–3 years 2319 (41.0) 441 (47.4)
>3 years 837 (14.8) 254 (27.3)
Positive Hepatitis C serology (%) 156 (2.8) 26 (2.8) 0.95
Previous blood transfusion (%) 1387 (24.5) 281 (30.2) <0.001
Panel reactive antibodies (SD) 7.3 (18.2) 9.2 (20.6) 0.008
Private health insurance (%) 2922 (51.7) 289 (31.0) <0.001
Education (%)
Less than high school 112 (2.4) 11 (1.5) 0.30
High school 2089 (44.8) 337 (45.5)
College 2465 (52.8) 392 (53.0)
Peripheral vascular disease (%) 402 (7.1) 45 (4.8) 0.01
Coronary artery disease (%) 515 (9.1) 46 (4.9) <0.001
Donor age (years) (SD) 26.9 (10.8) 26.0 (10.0) 0.007
Donor BMI (kg/m2) (SD) 23.9 (4.1) 24.2 (4.2) 0.10
Donor gender, male (%) 3827 (67.7) 611 (65.6) 0.22
Donor race, AA (%) 756 (13.4) 220 (23.6) <0.001
Donor smoking, >20 pack-years (%) 1352 (23.9) 206 (22.1) 0.24
Donor type, SCD (%) 5523 (97.7) 917 (98.5) 0.12
Donor hypertension (%) 378 (6.7) 57 (6.1) 0.52
Donor stroke (%) 1326 (23.5) 213 (22.9) 0.70
Serum creatinine at donation (mg/dL) (SD) 1.0 (0.8) 1.0 (0.5) 0.39
Cold ischemia time (h) (SD) 12.5 (5.4) 12.3 (5.7) 0.41
Delayed graft function (%) 408 (7.2) 121 (13.0) <0.001
HLA mismatches (SD) 4.4 (1.3) 4.7 (1.0) <0.001
Surgical technique (%) 0.87
Enteric drainage 4627 (81.8) 764 (82.1)
Bladder drainage 1027 (18.2) 167 (17.9)
Center volume (number/year) (%) <0.001
≤10 2403 (42.5) 414 (44.5)
11–20 1534 (27.1) 323 (34.7)
>20 1717 (30.4) 194 (20.8)
Induction agents (%) <0.001
ALG/OKT3 2643 (46.8) 427 (50.7)
IL-2R blockers 1361 (24.1) 175 (18.8)
Alemtuzumab 447 (7.9) 47 (5.1)
None 1203 (21.3) 237 (25.5)
Calcineurin inhibitors (%) 0.09
Tacrolimus 4911 (86.9) 833 (89.5)
Cyclosporine 518 (9.1) 68 (7.3)
None 225 (4.0) 30 (3.2)
Antiproliferatives (%) 0.004
MMF/MPA 4681 (82.8) 813 (87.3)
mTor inhibitors 637 (11.3) 82 (8.8)
None 300 (5.3) 34 (3.7)
Steroids, yes (%) 5431 (96.1) 899 (96.6) 0.46
CMV donor/recipient pair (%) <0.001
Negative/negative 1236 (21.9) 117 (12.6)
Negative/positive 1744 (30.9) 191 (20.5)
Positive/positive 1421 (25.1) 345 (37.1)
Positive/negative 896 (15.9) 207 (22.2)
Unknown 357 (6.3) 71 (7.6)
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Table 2: Risk factors associated with early graft failure within 90 days after transplantation
Kidney graft loss Pancreas graft loss
Variables OR 95% CI p-Value OR 95% CI p-Value
Recipient race, AA 1.09 0.70, 1.69 0.72 0.92 0.71, 1.18 0.44
Recipient gender, male 0.61 0.43, 0.88 0.007 0.74 0.62, 0.88 <0.001
Recipient BMI (kg/m2) 1.01 0.98, 1.06 0.48 1.03 1.01, 1.05 0.005
Cold ischemia time (h) 0.97 0.94, 1.01 0.13 1.01 0.99, 1.03 0.07
Delayed graft function 15.75 10.96, 22.62 <0.001 1.69 1.27, 2.26 <0.001
Donor age (years) 1.02 1.00, 1.03 0.05 1.02 1.01, 1.03 <0.001
Donor race, AA 1.66 1.08, 2.54 0.02 1.11 0.88, 1.42 0.38
Donor hypertension 1.86 1.09, 3.15 0.02 1.52 1.11, 2.08 0.01
Donor stroke 1.16 0.76, 1.75 0.50 1.26 1.00, 1.57 0.05
Bladder pancreas drainage 1.59 1.07, 2.37 0.02 0.84 0.66, 1.06 0.14
Center volume (number/year) (%) 0.40 <0.001
≤10 (42.8) Ref Ref Ref Ref Ref Ref
11–20 (28.2) 0.75 0.49, 1.15 0.19 0.82 0.66, 1.06 0.06
>20 (29.0) 0.97 0.63, 1.47 0.59 0.65 0.52, 0.80 <0.001
recipients (OR 1.35, 95% CI 1.13, 1.61, p < 0.001),
elevated recipient BMI (OR 1.03, 95% CI 1.01, 1.05,
p = 0.005), delayed kidney graft function (OR 1.69, 95%
1.27, 2.26, p < 0.001), older donor age (OR 1.02, 95% CI
1.01, 1.03, p < 0.001), donors with history of hypertension
or died of stroke (OR 1.52, 95% CI 1.11, 2.08, p = 0.01, and
OR 1.26, 95% CI 1.00, 1.57, p = 0.05, respectively) and
lower transplant center SPK volume were each associated
with increased risk of early pancreas graft loss (Table 2).
During subsequent follow-up, 544 kidney and 513 pancreas
grafts were lost. There was a significant difference in the
overall outcome of SPK transplantation between AA and
non-AA patients (Figure 1A, log-rank, p < 0.0001). This
difference was mainly due to higher death-censored graft
failure rate among AA SPK transplant patients for both kid-
ney and pancreas (Figures 1B and C, log-rank, p < 0.0001
for both), but not for death (data not shown). This differ-
ence was evident early within the first posttransplant year,
with actuarial 1, 3 and 5 years kidney and pancreas graft
survivals significantly lower for AA SPK transplant patients
compared to non-AA SPK transplant patients (Figure 2A
and B). Conditional multivariate Cox regression analyses
incorporating various confounding factors demonstrated
that AA SPK transplant patients have significantly higher
adjusted hazard for death-censored kidney graft failure
(HR 1.38, 95% CI, 1.11, 1.73, p = 0.006) and for death-
censored pancreas graft failure (HR 1.47, 95% CI, 1.17,
1.85, p = 0.001) (Table 3). When subgroup analyses were
performed including only SPK patients with a diagnosis of
type 1 diabetes the results remained unchanged (data not
shown). Additional risk factors associated with late kidney
graft failure were higher degree of HLA mismatch (HR 1.12,
95% CI 1.04, 1.20, p = 0.002), delayed graft function (HR
1.38, 95% CI 1.01, 1.88, p = 0.04), older donor age (HR
1.01, 95% CI 1.01, 1.02, p = 0.01), AA donors (HR 1.73,
95% CI 1.39, 2.16, p < 0.001) and more than 20 pack-
years smoking history in donors (HR 1.31, 95% CI 1.07,
1.59, p = 0.008). On the other hand, only donor age (HR
1.01, 95% CI 1.01, 1.02, p = 0.001) and AA donors (HR
1.49, 95% CI 1.17, 1.88, p = 0.001) were associated with
increased risk of late pancreas graft failure. Contrary to its
negative impact on early pancreas graft survival, transplant
center volume did not affect late pancreas graft outcome.
Immunological complication, acute and chronic rejection,
was the leading cause of late graft failure, accounting for
63.6% of kidney and 53.4% of pancreas graft loss, respec-
tively. In particular, compared to non-AA SPK transplant
patients, AA SPK transplant patients had a higher rate of
acute and chronic rejection as the reported cause of kid-
ney (80.3% vs. 58.9%, p < 0.001) and pancreas (65.7%
vs. 50.1%, p = 0.004) failure and were twice more likely
to lose their transplants due to rejection (OR 2.31, 95% CI
1.37, 3.87, p = 0.002 for kidney loss, and OR 1.86, 95%
CI 1.18, 2.95, p = 0.008 for pancreas loss).
The recipient race has no effect on patient survival (HR
1.05, 95% CI 0.80, 1.39, p = 0.72). Older recipient age
(HR 1.02, 95% CI 1.01, 1.03, p = 0.001), longer duration of
dialysis (HR 1.07, 95% CI 1.03, 1.11, p < 0.001), history of
blood transfusion (HR 1.28, 95% CI 1.06, 1.56, p = 0.01),
history of coronary artery disease (HR 1.42, 95% CI 1.09,
1.84, p = 0.01), AA donors (HR 1.52, 95% CI 1.19, 1.94,
p < 0.001) and stroke as the cause of death in donors
(HR 1.31, 95% CI 1.07, 1.61, p = 0.01) were associated
with increased risk for death (Table 4). The surgical modal-
ity in exocrine pancreas anastomosis did not affect long-
term pancreas and kidney graft survival (HR 1.01, 95% CI
0.82, 1.26, p = 0.90 for pancreas, and HR1.17, 95% CI
0.94, 1.45, p = 0.16 for kidney, respectively), but the blad-
der drainage was associated with increased risk for death
(overall death and death with graft function) after adjusting
for the effects of transplant era (HR 1.42, 95% 1.15, 1.75,
p < 0.001).
Discussion
This study showed that despite the absence of racial
differences in the early outcome of SPK transplants,
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Figure 1: Kaplan–Meier survival
analyses between AA and non-AA
SPK transplant patients, (A) overall
event free survival, (B) death cen-
sored kidney graft survival and (C)
death censored pancreas graft sur-
vival.
the long-term outcome of SPK transplants remains
significantly inferior for AA SPK transplant patients
in the recent era of modern immunosuppressive
therapy.
The racial disparity in the outcome of chronic kidney dis-
ease in general, and of kidney transplantation in particu-
lar has been widely documented over the past 20 years
(15,23,33). For example, AA kidney transplant patients
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Figure 2: Actuarial graft survival at 1, 3 and 5 years between
AA and non-AA SPK transplant patients, (A) kidney and (B)
pancreas.
have an inferior kidney graft survival compared to non-AA
kidney transplant patients and such difference has been at-
tributed to multiple factors including enhanced immune re-
activity and lower socioeconomic status (23,33–35). With
enhanced immunosuppression, the incidence of acute re-
jection has been significantly lowered in all categories of
transplant patients (34,36,37). However, the reduction in
acute rejection has not lead to the elimination of gap in
the outcome between AA and non-AA kidney transplant
patients (37).
Previous studies of the outcome of simultaneous pancreas
and kidney transplantation have included small numbers of
AA SPK transplant patients involved in the clinical trials or
in single center experiences (26,27,38). Rogers et al. com-
pared 33 AA to 63 non-AA SPK transplant patients and
found significantly lower pancreas graft survival at 1, 3 and
5 years after transplantation (26). The authors also reported
inferior late graft function and metabolic control in AA SPK
transplant patients (28). Zhang et al. reported, on the other
hand, comparable outcome in kidney and pancreas graft
survival after 5 years follow-up between 36 AA and 55 non-
AA SPK transplant patients (27). In studies comparing the
outcome of SPK versus kidney transplant alone using large
registry data, AA patients had higher risk for kidney graft
failure compared to non-AA patients (21,39). This study is
the first comprehensive analysis of racial effects on the
outcome of simultaneous pancreas and kidney transplan-
tation in the United States. The use of large sample size
and the consideration of multiple important demographic
and clinical variables allowed us to obtain a reliable assess-
ment of racial disparity among SPK transplant patients. By
analyzing separately the early and late outcome, we were
able to delineate the predominant nature of graft failure
that occurred during each of the two sequential periods.
Whereas the improvement in surgical techniques and pe-
rioperative management has probably contributed to the
equal early outcome between AA and non-AA SPK trans-
plant patients, the use of more modern immunosuppres-
sion has failed to eliminate the gap in long-term graft sur-
vival, both kidney and pancreas, between AA and non-AA
SPK transplant patients. Such difference in the late graft
outcome was not related to the inclusion of a small num-
ber of type 2 diabetic SPK transplant patients as subgroup
analyses including only type 1 diabetic SPK transplant
patients yielded identical results. On the other hand, al-
though we did not include early acute rejection episode
as one of the covariates in the analyses due to incom-
pleteness of such information in OPTN/SRTR data (more
than 40% missing data at 6 and 12 months follow-up), the
fact that AA-SPK transplant patients had more immune-
mediated kidney and pancreas graft failure, consistent with
findings from previous clinical trial (40), suggests that inad-
equate immunosuppression, either as result of an inherent
biological phenomenon or consequence of poor adherence
to prescribed immunosuppressive regimens, or other yet
Table 3: Risk factors associated with late graft loss among SPK transplant patients who survived up to 90 days with both graft function
Kidney graft loss Pancreas graft loss
Variables HR 95% CI p HR 95% CI p
Recipient race, AA (non-AA) 1.38 1.10, 1.73 0.006 1.47 1.17, 1.85 0.001
Recipient age, (years) 0.97 0.96, 0.99 <0.001 0.96 0.95, 0.97 <0.001
Duration of diabetes, (years) 0.97 0.96, 0.98 <0.001 0.99 0.97, 1.01 0.10
HLA mismatch, (zero) 1.12 1.04, 1.20 0.002 0.98 0.91, 1.04 0.45
Donor age, (years) 1.01 1.01, 1.02 0.01 1.01 1.01, 1.02 0.001
Donor race, AA (non-AA) 1.73 1.39, 2.16 <0.001 1.49 1.17, 1.88 0.001
Donor smoking, (>20 pack-years) 1.31 1.07, 1.59 0.008 1.18 0.97, 1.45 0.10
Delayed graft function, yes (no) 1.38 1.01, 1.88 0.04 0.88 0.61, 1.27 0.50
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Table 4: Risk factors associated with late death among SPK trans-
plant patients who survived 90 days with both graft function
Variables HR 95% CI p
Recipient race, AA
(non-AA)
1.05 0.80, 1.39 0.72
Recipient age, (years) 1.02 1.01, 1.03 0.001
Duration of dialysis, (years) 1.07 1.03, 1.11 <0.001
History of blood
transfusion, yes (no)
1.28 1.06, 1.56 0.01
History of coronary artery
disease, yes (no)
1.42 1.09, 1.84 0.01
Donor stroke, yes (no) 1.31 1.07, 1.61 0.01
Bladder pancreas drainage,
(enteric)
1.42 1.15, 1.75 0.001
Donor race, AA (non-AA) 1.52 1.19, 1.94 <0.001
identified factors, could be responsible for the observed
difference in the graft outcome.
Among many other factors that are involved in determin-
ing the graft and patient survival, the effect of donor race
appears unique in that the use of organs from AA donors
was associated with increased risk for inferior outcome.
Several studies of large registry data analyses have previ-
ously documented similar findings for kidney graft survival
in kidney as well as in SPK transplant patients (21,39,41).
The mechanism for such observed difference remains un-
clear despite adjustment of multiple potential confounding
factors. The statistically significant difference conferred by
donor race, however, does not appear clinically relevant
as the difference in actual kidney, pancreas graft loss and
death was about 4.7%, 2.2% and 3.4% after 8 years follow-
up, respectively. Most importantly, survival advantage of
SPK transplantation over dialysis was clearly demonstrated
regardless of donor source (2,42). Nevertheless, it is im-
portant to recognize such donor race effect so that future
studies can be conducted to improve our understanding of
such phenomenon.
A notable finding in this study is the impact of surgical
modality in exocrine pancreas anastomosis on the out-
come of SPK transplantation. Although bladder drainage
did not appear to affect pancreas and kidney graft loss, it
was associated with higher risk for patient death, overall
and with graft function. Possible explanation for the in-
creased risk for death could be related to patient selection
bias, higher rate of infectious and metabolic complications
associated with bladder drainage and/or the need for en-
teric conversion in many instances or other as yet poorly
understood mechanisms (43).
There are several limitations related to our study. The pos-
sibility of confounding for variables that were not collected
by OPTN/SRTR could bias our conclusion in one way or
another. In addition, such study also is not able to take
into consideration of factors that were important in deter-
mining the outcome and that are measured during trans-
plant follow-up, such as the degree of blood pressure and
glycemic control, compliance with medical care and follow-
up, etc., between AA and non-AA SPK transplant patients.
We were not able, for example, to study pancreas en-
docrine function as data such as fasting glycemia, glycated
hemoglobin or use of insulin, etc., was not routinely col-
lected by OPTN/SRTR. As always, association should not
be inferred as causality, rather as suggestion that additional
studies are needed in the field.
In conclusion, despite the improvement in surgical tech-
niques and perioperative care, and the use of potent im-
munosuppressive regimens in the most recent era, AA
SPK patients continue to have inferior kidney and pancreas
graft survival. Additional studies are needed to improve
our understanding and to reduce such racial disparity on
the outcome.
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